Palisade Bio Financial Results
Palisade Bio reported third quarter 2026 financial results and provided a clinical update on its PALI-2108 programs, including the initiation of the Phase 2b ASCENTRA-UC trial. The company ended the quarter with $113.6 million in cash and expects topline results from the UC trial in Q4 2027.
“ASCENTRA-UC is now underway, and our focus is on driving enrollment and executing the study to deliver topline results in the fourth quarter of 2027. With nearly all planned U.S. sites activated, we are expanding our global clinical footprint to build on that progress.”
JD Finley, Chief Executive Officer of Palisade Bio
“In parallel, we are preparing to initiate ASCENTRA-CD, with initiation of enrollment targeted for the first quarter of 2027. Our strong financial position supports execution across both programs as we work to establish PALI-2108’s potential as a differentiated, once-daily oral treatment for patients living with IBD.”
JD Finley, Chief Executive Officer of Palisade Bio